Throughout the last three months, 27 analysts have evaluated Alnylam Pharmaceuticals (NASDAQ:ALNY), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 13 | 11 | 3 | 0 | 0 |
| Last 30D | 1 | 0 | 1 | 0 | 0 |
| 1M Ago | 2 | 3 | 0 | 0 | 0 |
| 2M Ago | 3 | 0 | 0 | 0 | 0 |
| 3M Ago | 7 | 8 | 2 | 0 | 0 |
Analysts have set 12-month price targets for Alnylam Pharmaceuticals, revealing an average target of $463.74, a high estimate of $583.00, and a low estimate of $348.00. This current average has increased by 18.98% from the previous average price target of $389.76.
Analyzing Analyst Ratings: A Detailed Breakdown
The analysis of recent analyst actions sheds light on the perception of Alnylam Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Michael Ulz | Morgan Stanley | Raises | Equal-Weight | $475.00 | $405.00 |
| Paul Matteis | Stifel | Raises | Buy | $495.00 | $441.00 |
| Luca Issi | RBC Capital | Raises | Outperform | $500.00 | $435.00 |
| Tazeen Ahmad | B of A Securities | Raises | Buy | $520.00 | $453.00 |
| Salveen Richter | Goldman Sachs | Raises | Buy | $566.00 | $504.00 |
| Liisa Bayko | Evercore ISI Group | Raises | Outperform | $515.05 | $280.00 |
| Kostas Biliouris | BMO Capital | Raises | Outperform | $470.00 | $450.00 |
| Patrick R. Trucchio | HC Wainwright & Co. | Maintains | Buy | $570.00 | $570.00 |
| David Lebovitz | Citigroup | Raises | Buy | $583.00 | $527.00 |
| Patrick Trucchio | HC Wainwright & Co. | Raises | Buy | $570.00 | $500.00 |
| Jessica Fye | JP Morgan | Raises | Overweight | $475.00 | $348.00 |
| Leland Gershell | Oppenheimer | Announces | Outperform | $490.00 | - |
| Greg Harrison | Scotiabank | Raises | Sector Outperform | $450.00 | $342.00 |
| Eliana Merle | UBS | Raises | Buy | $550.00 | $403.00 |
| Whitney Ijem | Canaccord Genuity | Raises | Buy | $415.00 | $390.00 |
| Tiago Fauth | Wells Fargo | Raises | Equal-Weight | $395.00 | $333.00 |
| Martin Auster | Raymond James | Raises | Outperform | $424.00 | $370.00 |
| Gena Wang | Barclays | Raises | Overweight | $460.00 | $329.00 |
| Edward Tenthoff | Piper Sandler | Raises | Overweight | $449.00 | $304.00 |
| Keay Nakae | Chardan Capital | Raises | Buy | $400.00 | $325.00 |
| Michael Ulz | Morgan Stanley | Raises | Equal-Weight | $405.00 | $312.00 |
| Joseph Stringer | Needham | Raises | Buy | $478.00 | $377.00 |
| Martin Auster | Raymond James | Raises | Outperform | $370.00 | $308.00 |
| Danielle Brill | Truist Securities | Announces | Buy | $385.00 | - |
| Jessica Fye | JP Morgan | Raises | Overweight | $348.00 | $338.00 |
| David Lebovitz | Citigroup | Raises | Buy | $404.00 | $364.00 |
| Tazeen Ahmad | B of A Securities | Raises | Buy | $359.00 | $336.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alnylam Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Alnylam Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Alnylam Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Alnylam Pharmaceuticals analyst ratings.
All You Need to Know About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Alnylam Pharmaceuticals: A Financial Overview
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Alnylam Pharmaceuticals's revenue growth over a period of 3M has been noteworthy. As of 30 June, 2025, the company achieved a revenue growth rate of approximately 17.26%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Alnylam Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -8.57%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -36.21%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.51%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 5.18, Alnylam Pharmaceuticals faces challenges in effectively managing its debt levels, indicating potential financial strain.
The Core of Analyst Ratings: What Every Investor Should Know
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
